• 1
    Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012; 61: 1079-1092.
  • 2
    Hussain S, Gunnell D, Donovan J, et al. Secular trends in prostate cancer mortality, incidence and treatment: England and Wales, 1975-2004. BJU Int. 2008; 101: 547-555.
  • 3
    Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol. 1993; 150( 2 pt 1): 379-385.
  • 4
    Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003; 349: 215-224.
  • 5
    Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med. 2004; 350: 2239-2246.
  • 6
    Fleming C, Wasson JH, Albertsen PC, Barry MJ, Wennberg JE. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team. JAMA. 1993; 269: 2650-2658.
  • 7
    Albertsen PC. The prostate cancer conundrum. J Natl Cancer Inst. 2003; 95: 930-931.
  • 8
    National Cancer Institute Cancer Intervention and Surveillance Modeling Network (CISNET). Prostate Cancer Model Profiles. Accessed June 13, 2012.
  • 9
    Etzioni R, Gulati R, Tsodikov A, et al. The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. Cancer. 2012; 118: 5955-5963.
  • 10
    Moyer VA; on behalf of the U.S. Preventive Services Task Force. Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement [published online ahead of print May 21, 2012]. Ann Intern Med.
  • 11
    Sciarra A, Panebianco V, Salciccia S, et al. Value of magnetic resonance spectroscopy (MSR) and dynamic contrast-enhanced magnetic resonance (DCEMR) imaging for the characterization of high-grade prostatic intraepithelial neoplasia (HGPIN) foci. Urol Oncol. 2011; 29: 634-640.
  • 12
    Roobol MJ, Schroeder FH, van Leeuwen P, et al. Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. Eur Urol. 2010; 58: 475-481.
  • 13
    Schroder FH, Hugosson J, Roobol MJ, et al; ERSPC Investigators. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 2012; 366: 981-990.
  • 14
    Andriole GL, Crawford ED, Grubb RL3rd, et al; PLCO Project Team. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012; 104: 125-132.
  • 15
    Lane JA, Hamdy FC, Martin RM, Turner EL, Neal DE, Donovan JL. Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies. Eur J Cancer. 2010; 46: 3095-3101.
  • 16
    Wilt TJ. The Prostate Cancer Intervention Versus Observation Trial (PIVOT) in NIH State of the Science Conference: Role of Active Surveillance in the Management of Men with Localized Prostate Cancer. National Institutes of Health, December 5-7, 2011;105106.
  • 17
    Donovan J, Hamdy F, Neal D, et al. ProtecT Study Group. Prostate Testing for Cancer and Treatment (ProtecT) feasibility study. Health Technol Assess 2003;7:188.